ADMA Biologics

ADMA Biologics is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics primarily for the treatment of immune deficiencies and infectious diseases. The company's product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin products used for treating primary humoral immunodeficiency, as well as Nabi-HB, which is indicated for exposure to Hepatitis B. ADMA serves niche patient populations, particularly those who are immunocompromised or immune-suppressed due to medical conditions. To support its product development, ADMA operates FDA-licensed plasma collection facilities known as ADMA BioCenters, which supply plasma for its biologics. The company distributes its products through a network of independent distributors, specialty pharmacies, and alternate site providers. Founded in 2004 and headquartered in Ramsey, New Jersey, ADMA Biologics continues to advance its pipeline of plasma-derived therapeutics aimed at preventing and treating infections.